Nothing Special   »   [go: up one dir, main page]

WO2001032631A3 - Heterocyclic cytotoxic agents - Google Patents

Heterocyclic cytotoxic agents Download PDF

Info

Publication number
WO2001032631A3
WO2001032631A3 PCT/US2000/029583 US0029583W WO0132631A3 WO 2001032631 A3 WO2001032631 A3 WO 2001032631A3 US 0029583 W US0029583 W US 0029583W WO 0132631 A3 WO0132631 A3 WO 0132631A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
heterocyclic
cytotoxic agents
compounds
preparing compounds
Prior art date
Application number
PCT/US2000/029583
Other languages
French (fr)
Other versions
WO2001032631A2 (en
Inventor
Edmond J Lavoie
Leroy Fong Liu
Younong Yu
Original Assignee
Univ Rutgers
Edmond J Lavoie
Leroy Fong Liu
Younong Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers, Edmond J Lavoie, Leroy Fong Liu, Younong Yu filed Critical Univ Rutgers
Priority to EP00973917A priority Critical patent/EP1228045A2/en
Priority to JP2001534782A priority patent/JP2003513079A/en
Priority to CA002389312A priority patent/CA2389312A1/en
Priority to AU12364/01A priority patent/AU1236401A/en
Publication of WO2001032631A2 publication Critical patent/WO2001032631A2/en
Publication of WO2001032631A3 publication Critical patent/WO2001032631A3/en
Priority to US10/134,983 priority patent/US6740650B2/en
Priority to US10/853,017 priority patent/US20050009830A1/en
Priority to US11/118,071 priority patent/US7466663B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compounds of formula (I), wherein R1-R8 ang A-G have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for treating cancer using compounds of formula (I).
PCT/US2000/029583 1999-10-29 2000-10-26 Heterocyclic cytotoxic agents WO2001032631A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00973917A EP1228045A2 (en) 1999-10-29 2000-10-26 Heterocyclic cytotoxic agents
JP2001534782A JP2003513079A (en) 1999-10-29 2000-10-26 Heterocyclic cytotoxic agent
CA002389312A CA2389312A1 (en) 1999-10-29 2000-10-26 Heterocyclic cytotoxic agents
AU12364/01A AU1236401A (en) 1999-10-29 2000-10-26 Heterocyclic cytotoxic agents
US10/134,983 US6740650B2 (en) 1999-10-29 2002-04-29 Heterocyclic cytotoxic agents
US10/853,017 US20050009830A1 (en) 1999-10-29 2004-05-25 Heterocyclic cytotoxic agents
US11/118,071 US7466663B2 (en) 2000-10-26 2005-04-29 Method and apparatus for identifying components of a network having high importance for network integrity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16254099P 1999-10-29 1999-10-29
US60/162,540 1999-10-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/134,983 Continuation US6740650B2 (en) 1999-10-29 2002-04-29 Heterocyclic cytotoxic agents
US11/118,071 Continuation US7466663B2 (en) 2000-10-26 2005-04-29 Method and apparatus for identifying components of a network having high importance for network integrity

Publications (2)

Publication Number Publication Date
WO2001032631A2 WO2001032631A2 (en) 2001-05-10
WO2001032631A3 true WO2001032631A3 (en) 2002-02-21

Family

ID=22586069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029583 WO2001032631A2 (en) 1999-10-29 2000-10-26 Heterocyclic cytotoxic agents

Country Status (6)

Country Link
EP (1) EP1228045A2 (en)
JP (1) JP2003513079A (en)
AR (1) AR026267A1 (en)
AU (1) AU1236401A (en)
CA (1) CA2389312A1 (en)
WO (1) WO2001032631A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047505A2 (en) 2001-11-14 2003-06-12 Rutgers, The State University Topoisomerase poison agents
EP2196205A1 (en) 2001-11-14 2010-06-16 Rutgers, The State University Topoisomerase poisons
EP1453812B1 (en) 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
DE60231426D1 (en) * 2001-11-14 2009-04-16 Univ Rutgers SOLUBILIZED TOPOISOMERASE GIFT MEDIUM
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
WO2004014906A2 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
WO2004014918A1 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
CA2510337C (en) * 2002-11-12 2013-01-08 Rutgers, The State University Of New Jersey Topoisomerase-targeting agents
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
DE102008022221A1 (en) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitors of human aldosterone synthase CYP11B2
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
WO2010102219A1 (en) 2009-03-06 2010-09-10 Rutgers, The State University Of New Jersey Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (en) 2014-03-28 2023-04-28 Duke University Treating breast cancer using selective estrogen receptor modulators
EP3442979A4 (en) 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey Topoisomerase poisons

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045272A1 (en) * 1997-04-07 1998-10-15 Latrobe University Topoisomerase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045272A1 (en) * 1997-04-07 1998-10-15 Latrobe University Topoisomerase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALTIPARMAKIAN, R. H. ET AL: "Diprotonation of polynuclear cinnolines in sulfuric acid", J. CHEM. SOC. B (1967), (11), 1112-13, XP002170332 *

Also Published As

Publication number Publication date
AU1236401A (en) 2001-05-14
EP1228045A2 (en) 2002-08-07
WO2001032631A2 (en) 2001-05-10
JP2003513079A (en) 2003-04-08
CA2389312A1 (en) 2001-05-10
AR026267A1 (en) 2003-02-05

Similar Documents

Publication Publication Date Title
WO2001032631A3 (en) Heterocyclic cytotoxic agents
GB0119249D0 (en) Organic compounds
TW200502230A (en) Dual nk1/nk3 derivatives
ZA200707901B (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2003041660A3 (en) Solubilized topoisomerase poisons
WO2006016067A3 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU3850600A (en) Dalda analogs and their use
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
DE69907419D1 (en) Antitumorwirkstoffe
WO2003047505A3 (en) Topoisomerase poison agents
EP1453507A4 (en) Solubilized topoisomerase poison agents
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
EP1109560A4 (en) Compounds useful as aicarft inhibitors
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
WO2004044174A3 (en) Topoisomerase-targeting agents
TW200510370A (en) Urea derivatives
WO2003051276A3 (en) Therapeutic heterocycles
MY133682A (en) Substituted pyrroles
AU2003218141A1 (en) Potent, simplified derivatives of immunosuppressive agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2389312

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 534782

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 12364/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000973917

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000973917

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000973917

Country of ref document: EP